Article detail · 2018 · article
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Journal
The Lancet
OpenAlex
Top 1%
Year2018
Citations941OpenAlex
Citations831Semantic Scholar · 69 influential
Percentile%100.0
FWCI65.331.00 = world average
Scopus (SJR)Q1
WoS (JCR)Q1
Data source split
- YÖKSİS venueThe Lancet
- OpenAlexOpenAlex enrichment (abstract, citations, topics)
- Semantic Scholarcitation count (not merged with OpenAlex)
Abstract
Abstract not compiled yet; it will appear after the DergiPark / OpenAlex queue runs.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
941citationsOpenAlex · cited_by_count (cache / database)
12 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- 2025 Tolebrutinib in Nonrelapsing Secondary Progressive Multiple SclerosisCitations 135 · OpenAlex
- 2020 Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialCitations 108 · OpenAlex
- 2020 Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialCitations 107 · OpenAlex
- 2020 Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple SclerosisCitations 36 · OpenAlex
- 2021 Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple SclerosisCitations 29 · OpenAlex
- 2021 Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple SclerosisCitations 29 · OpenAlex
- 2024 Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60Citations 21 · OpenAlex
- 2023 Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisCitations 10 · OpenAlex
- 2024 Effects of disease-modifying therapies on remyelination in multiple sclerosis; evaluation via visual evoked potential testCitations 8 · OpenAlex
- 2024 Effects of disease-modifying therapies on remyelination in multiple sclerosis; evaluation via visual evoked potential testCitations 6 · OpenAlex
Authors
No author information.